76596-53-7

Usage

Uses

Used in Chemical Synthesis:
Ethanone, 1-(3-bromo-5-isoxazolyl)is used as a synthetic intermediate for the production of various organic compounds. Its unique structure, including the bromine atom and isoxazole ring, allows it to participate in a range of chemical reactions, facilitating the synthesis of complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Ethanone, 1-(3-bromo-5-isoxazolyl)is used as a building block for the development of new drugs. Its chemical properties and reactivity make it a valuable component in the creation of novel pharmaceutical compounds with potential therapeutic applications.
Used in Research and Development:
Ethanone, 1-(3-bromo-5-isoxazolyl)is utilized in research and development settings to explore its chemical properties and potential applications. Scientists and researchers use Ethanone, 1-(3-bromo-5-isoxazolyl)- to investigate its reactivity, stability, and interactions with other molecules, which can lead to the discovery of new chemical processes and applications.
Used in Material Science:
In the field of material science, Ethanone, 1-(3-bromo-5-isoxazolyl)may be employed in the development of new materials with specific properties. Its unique structure and reactivity can contribute to the creation of materials with tailored characteristics for various applications, such as in electronics, coatings, or adhesives.

Upstream product

• 105174-96-7 1-(3-Bromo-5-isoxazolyl)ethanol 
• 7664-93-9 sulfuric acid 
• 105-53-3 diethyl malonate 
• 6567-35-7 3-bromo-5-isoxazolecarboxylic acid 
• 74213-24-4 N-dibromomethylidenehydroxylamine 
• 13530-68-2 dichromic acid 
• 76596-52-6 3-bromo-5-isoxazolecarboxylic acid chloride 
• 1423-60-5 methyl ethynyl ketone 

Downstream Products

• 391935-82-3 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)benzenesulfonamide 
• 76596-57-1 Broxaterol 
• 76596-55-9 1-(3-bromo-5-isoxazolyl)-2-bromoethanol 

Relevant academic research and scientific papers

Tandem synthesis of 3-halo-5-substituted isoxazoles from 1-copper(I) alkynes and dihaloformaldoximes

A tandem synthesis of 3-halo-5-substituted isoxazoles has been developed from 1-copper(I) alkynes and dihaloformaldoximes under base-free conditions. Thus, 1,3-dipolar cycloaddition and all its drawbacks can now be avoided completely.

N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists

This invention provides compounds of Formula I having the structure wherein R1, R2, R3, R4, W, X, and Y are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.

Chemoenzymatic Synthesis of Chiral Isoxazole Derivatives

The synthesis of the two enantiomers of 1-(3-bromo-5-isoxazolyl)-2-(tert-butylamino)ethanol (1), a potent and selective β2-adrenergic stimulant, has been efficiently accomplished by enzyme-catalyzed transformations.The absolute configurations are attributed to (+)- and (-)-1 by correlation with (S)-3-butyn-2-ol.The S enantiomer was prepared in >98percent enantiomeric excess by reducing α-bromo ketone 4 in the presence of alcohol dehydrogenase from Thermoanaerobium brockii and the R enantiomer was obtained in 97percent ee through a kinetic resolution of the racemic bromohydrin(+/-)-5, in organic solvents, catalyzed by lipase P from Pseudomonas fluorescens.The experimental conditions for the lipase-catalyzed asymmetric transesterifications were optimized in order to improve reaction rates and the enantiomeric excess of the products.

Process for the preparation of 3,5-disubstituted isoxazoles

A novel process for the preparation of 3-bromo- and 3-chloro-5-substituted isoxazoles is provided. Dibromo- or dichloro-formaldoxime is reacted with an excess of an 1-alkyne derivative of the formula where R is hydrogen, phenyl or 1-6 C alkyl optionally substituted by halogen, OH, OR', CHO, COR', COOR', CONH2, CONR'R" or NHCOR' where, in turn, R' and R", which may be the same or different, are a 1-6 C alkyl or haloalkyl, in the presence of (i) at least an equimolecular amount, with respect to the dibromo- or dichloro-formaldoxime, of an alkaline base selected from the class consisting of sodium and potassium carbonate and bicarbonate and (ii) an inert solvent in which the 1-alkyne is soluble at room temperature.

1-(3-Bromo-isoxazol-5-yl)-2-tert.butylaminoethanol

A new isoxazole derivative and the preparation thereof are disclosed. 1-(3-Bromo-isoxazol-5-yl)-2-ter.butylaminoethanol endowed with therapeutic activity, in particular bronchodilating action is disclosed, as well as a method for preparing same from 3-bromo-5-isoxazolecarboxylic acid. New intermediate compounds as well as pharmaceutical compositions containing the novel isoxazole derivative are also disclosed.